The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line rilvegostomig (rilve) plus chemotherapy (CTx) in advanced biliary tract cancer (BTC): Primary analysis of GEMINI-Hepatobiliary substudy 2 Cohort A.
 
Jian Zhou
Consulting or Advisory Role - AstraZeneca; MSD
Research Funding - Akeso-Sino Pharma Co., Ltd. (Inst); AstraZeneca (Inst); BeiGene (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); Eddingpharm (Suzhou) Co., Ltd. (Inst); Eisai China Inc. (Inst); Fosun Pharma (Inst); Gilead Sciences (Inst); Innovent Biologics (Inst); Jiangsu Hengrui Medicine (Inst); Junshi Biosciences (Inst); MSD (Inst); OriCell Therapeutics Co.,Ltd. (Inst); Qilu Pharmaceutical (Inst); Roche (Inst); Singlera genomics (Inst); Suzhou Zelgen Biopharmaceuticals Co., Ltd. (Inst)
 
Hye Jin Choi
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Guardant Health; Incyte; Lilly Japan; MSD; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Delta-Fly Pharma; Eisai; GlaxoSmithKline; Guardant Health; MSD; Nihon Medi-Physics; Novartis; Ono Yakuhin; Rakuten Medical Japan; Roche; SERVIER
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)
 
Angela Lamarca
Consulting or Advisory Role - Albireo Pharma; AstraZeneca/MedImmune; Boehringer Ingelheim; Boston Scientific; EISAI; GENFIT; Ipsen; MSD Oncology; Nutricia; QED Therapeutics; Roche; SERVIER; Taiho Pharmaceutical; TransThera Biosciences
Speakers' Bureau - Advanced Accelerator Applications; Advanz Pharma; AstraZeneca/MedImmune; Eisai; Incyte; Ipsen; Merck; MSD Oncology; Novartis; Pfizer; QED Therapeutics; Roche; SERVIER
Research Funding - Albireo Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); GENFIT (Inst); Ipsen; Merck (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Roche (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Abbott Nutrition; Advanced Accelerator Applications; Advanz Pharma; Bayer; Celgene; Delcath Systems; Ipsen; Mylan; Novartis; Pfizer; Roche; Sirtex Medical
 
Do-Youn Oh
Consulting or Advisory Role - Abbvie; Alligtor Bioscience AB; Arcus Biosciences; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Eutilex; Genentech/Roche; Halozyme; Hana Pharm; Idience; IQVIA; J-Pharma; LG Chem; Merck Serono; Mirati Therapeutics; Moderna Therapeutics; MSD Oncology; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Tiziana Pressiani
Consulting or Advisory Role - AstraZeneca; Bayer
Research Funding - AstraZeneca; Roche
 
Ho Yeong Lim
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai
Speakers' Bureau - Bayer
 
Hong Jae Chon
Consulting or Advisory Role - Aptamer Sciences Inc; AstraZeneca; Bayer; BeiGene; BMS; Eisai; MSD; Ono Pharmaceutical; Roche; Sanofi; SERVIER
Speakers' Bureau - AstraZeneca; Bayer; BMS; Dong-A ST; Eisai; Roche; Sanofi; SERVIER
Research Funding - BeiGene (Inst); Boryung (Inst); Dong-A ST (Inst); Hanmi (Inst); inno-n (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Medivir (Inst)
 
Hyung-Don Kim
Honoraria - AstraZeneca/MedImmune; Boostimmune; Boryung Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Mustbio
Research Funding - Roche/Genentech/Foundation Medicine
 
Andrea Casadei Gardini
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Incyte; Ipsen; IQVIA; MSD; Roche; SERVIER
Speakers' Bureau - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Incyte; Ipsen; IQVIA; MSD; Roche; SERVIER
Research Funding - AstraZeneca/MedImmune; Eisai
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Ono Pharmaceutical; Eisai; IPSEN; MSD Oncology; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Genentech/Roche; Ipsen; IQVIA; MSD; Omega Therapeutics, Inc.; Roche
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Ruifan Xie
Employment - AstraZeneca/MedImmune
 
Jinfeng Xiang
Employment - AstraZeneca/MedImmune
 
Rui Miao
Employment - AstraZeneca/MedImmune
 
Olivia Aoli
Employment - AstraZeneca/MedImmune
 
Sujatha Muralidharan
Employment - AstraZeneca/MedImmune
 
Osama Rahma
Employment - AstraZeneca/MedImmune
Leadership - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune; Outcomes4Me
 
Rakesh Kumar
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
Patents, Royalties, Other Intellectual Property - AstraZeneca/MedImmune
 
Ghassan Abou-Alfa
Consulting or Advisory Role - Abbvie; Ability Pharma (I); Agenus (I); Alligator Bioscience (I); Arcus Ventures (I); Astellas Pharma (I); Astellas Pharma (I); AstraZeneca; Autem Medical; Berry Genomics; BioNtech (I); Boehringer Ingelheim (I); Bristol-Myers Squibb/Medarex (I); Fibrogen (I); Ipsen; J-Pharma; Merck Serono (I); Merus NV (I); Moma Therapeutics (I); Neogene Therapeutics (I); Novartis (I); Regeneron (I); Revolution Medicines (I); Roche/Genentech; Servier; Syros Pharmaceuticals (I); Tango Therapeutics (I); Tempus (I); Vector Health; Yiviva
Research Funding - Abbvie (Inst); Agenus (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); Atara Biotherapeutics (Inst); Beigene (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pertzye (Inst); Yiviva (Inst)